Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy

Journal of Nuclear Medicine

Volumn 37, Issue 1, 1996, Pages 146-150

  Shen, Sui ^a,b   DeNardo, Gerald L ^a   DeNardo, Sally J ^a   Salako, Qansy ^a   Morris, Geoffrey ^a   Banks, Danny ^a   Yuan, Aina ^a   DeNardo, Diane A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

copper 64; copper 67; radiation dosimetry; radioimmunotherapy

Indexed keywords

COPPER 64; COPPER 67;

ARTICLE; CALCULATION; DOSE RESPONSE; DOSIMETRY; IMAGE ANALYSIS; IMAGE ENHANCEMENT; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RADIATION DOSE; RADIATION SCATTERING; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA;

EID: 0030012729     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD radionuclide data and decay schemes New York: Society of Nuclear Medicine; 1989:72-75.
2. Jungerman JA, Yu KH, Zanelli CI. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy Int J Appl Radiat Isot 1984,35 883-888.
3. Wessels BW, Rogus RD Radionuclide selection and mode! absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984,11:638-645.
4. DeNardo GL, DeNardo SJ, O'Grady LF, Levy NB, Adams GP, Mills SL. Fractionated radioimmunotherapy of B-cell malignancies with I-131-Lym-1. Cancer Res 1990;50: 1014-1016.
5. Deshpande SV, DeNardo SJ, Meares CF, et al Copper-67 labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy:labeling and biodistribution in Raji tumored mice. J Nucl Med 1988;29.217-225.
6. DeNardo GL, DeNardo SJ, Meares CF, et al. Pharmacokinetics of copper-67 conjugated Lym-1, a potential therapeutic radioimmunoconjugate, in mice and in patients with lymphoma. Antibody Immunoconj Radiopharm 1991;4:777-785.
7. DeNardo GL, DeNardo SJ, Meares CF, et al. Pilot therapy of lymphoma with fractionated Cu-67-BAT-Lym-1 [Abstract]. J Nucl Med 1993;34(suppl):93P.
8. Delaloye AB, Buchegger F, Smith A, et al. Cu-67-Anti-CEA Mab, a potential therapeutic agent, biokinetic studies in patients with colon carcinoma [Abstract]. J Nucl Med 1994;35(suppl):101P.
9. Dasgupta AK, Mausner LF, Srivastava SC. A new separation procedure for Cu-67 from proton irradiated Zn Int J Rad Appl Instrum [A] 1991;42:371-376.
10. Kukis DL, Diril H, Greiner DP, DeNardo SJ, DeNardo GL, CF Meares. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates Cancer 1994(Suppl)73:779-786.
11. DeNardo GL, DeNardo SJ, Macey DJ, Mills SL. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients In: Srivastava SC, ed. Radiolabeled monoclonal antibodies for imaging and therapy. New York: Plenum; 1988:293-310.
12. Macey DJ, DeNardo GL, DeNardo SJ. A treatment planning program for radioimmunotherapy. In: Vaeth JM, Meyer JL, eds. Frontiers of radiation therapy and oncology. Basel Karger; 1990:123-131.
13. Shen S, DeNardo GL, DeNardo SJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys 1994;21 1409-1417.
14. Sorenson JA Methods of correcting Anger camera deadtime losses. J Nucl Med 1976,17:137-141.
15. Loevinger R, Berman M. A revised schema for calculating the absorbed dose, from biologically distributed radionuclides. MIRD pamphlet no 1. New York: Society of Nuclear Medicine; 1976.
16. Snyder WS, Ford MR, Warner GG, Waston SB. S, " Absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD pamphlet no. 11, New York: Society of Nuclear Medicine, 1975.
17. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of B cell malignancies with I-131-Lym-1 monoclonal antibodies. Int J Cancer 1988;3:96-101.
18. DeNardo GL, Mahe MA, DeNardo SJ, et al. Body and blood clearance and marrow radiation dose of I-131-Lym-1 in patients with B-cell malignancies. Nucl Med Commun 1993;14:587-595.
19. Siegel JA, Wessels BW, Waston EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm 1990;3.213-233.
20. Sgouros G. Bone marrow dosimetry for radioimmunotherapy theoretical considerations. J Nucl Med 1993;34.689-694.
21. Colombetti LG, Johnston AS. Absorbed radiation dose by the thyroid from radioiodine impurities found in 1-123. Int J Appl Radiat Isot 1976;27:656-659.
22. Lagunas-Solar MC, Hines HH. Effects of radionuclide composition on dosimetry and scintillation-imaging characteristics of I-127(p, 5n)- and Tc-124(p, 2n)-made iodine-123 for nuclear medicine applications. In: Paras P, Thiessen JW, eds. The developing role of short-lived radionuclides in nuclear medical practice. Springfield, VA Office of Scientific and Technical Information; 1985.423-444.
23. Ziessman HA, Fahey FH, Gochoco JM. Impact of radiocontaminants in commercially available iodine-123. dosimetric evaluation. J Nucl Med 1986;27:428-432.
24. Apelgot S, Coppey J, Gaudemer A, et al. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, Cu-64 and Cu-67 Int J Radiol Biol 1989;55:365-384.
25. Anderson CJ, Connett JM, Baumann ML, et al. Comparison of Cu-67 and Cu-64 as potential radionuclides for radiotherapy [Abstract]. J Nucl Med 1993,34(suppl).134P.
26. Anderson CJ, Connett JM, Guo LW, et al. Initial comparison of Cu-67 and Cu-64-labeled anti-colorectal carcinoma Mab 1A3 agents for radioimmunotherapy in tumor-hearing hamsters [Abstract] J Nucl Med 1994;35(suppl) 161P.
27. McKeighen RE, Muehllehner G, Mayer RA Gamma camera collimator consideration for imaging I-123 J Nucl Med 1974;15:328-331.
28. Macey DJ, DeNardo GL, DeNardo SJ, Hines HH. Comparison of low- and medium-energy collimators for SPECT imaging with iodine-123-labeled antibodies. J Nucl Med 1986;27:1467-1474.
29. King M, Schwinger RB, Penney BC, Doherty PW, Bianco JA. Digital restoration of indium-111 and iodine-123 SPECT images with optimized Metz filters. J Nucl Med 1986,27:1327-1336.
30. Jaszczak RJ, Greer KL, Floyd CE, Harris CC, Coleman RE. Improved SPECT quantification using compensation for scattered photons. J Nucl Med 1984;25.893-900.
31. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S. A practical method for position-dependent Compton-scatter correction in single photon emission CT IEEE Trans Med Imag 1991;10:408-412.
32. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy implications for selecting radionuclides. J Nucl Med 1993;34:1801-1810.
33. Howell RW, Goddu SM, Rao DV. Application of the linear-quadratic model to radioimmunotherapy confirmation of the advantage of long-lived radionuclides J Nucl Med 1994,35:1861-1869.
34. 90Y-DOTA-peptide in tumor bearing mice J Nucl Med 1995;36:829-836.